Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience

PIK3CA activating mutations are found in 40% of advanced breast cancer and are associated with worse prognosis. PI3K blockage is associated with insulin resistance, leading to hyperglycemia and hyperinsulinemia. Alpelisib is the first PI3K inhibitor used in cancer treatment. Laboratory evidence indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Percik, Ruth, Oedegaard Smith, Cecilie, Leibovici, Anca, Shai, Ayelet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164376/
https://www.ncbi.nlm.nih.gov/pubmed/37163178
http://dx.doi.org/10.2147/BTT.S395817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164376/
https://www.ncbi.nlm.nih.gov/pubmed/37163178
http://dx.doi.org/10.2147/BTT.S395817

Ejemplares similares